<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>EM Weekly</title><description>Source-linked emergency medicine evidence</description><link>https://emweekly.samermetri.com/</link><language>en-us</language><item><title>PREOXI: a better start before intubation</title><link>https://emweekly.samermetri.com/articles/preoxi/</link><guid isPermaLink="true">https://emweekly.samermetri.com/articles/preoxi/</guid><pubDate>Mon, 26 Oct 2026 12:00:00 GMT</pubDate><description>Historical sample. PREOXI randomized 1,301 critically ill adults to NIV or an oxygen mask before intubation. Hypoxemia (SpO2 &lt;85%) occurred in 9.1% versus 18.5% (absolute difference -9.4 percentage points; 95% CI -13.2 to -5.6). AI-generated; Not yet human-reviewed.</description></item><item><title>AAP 2026: pediatric UTI diagnosis and treatment</title><link>https://emweekly.samermetri.com/articles/aap-pediatric-uti-2026/</link><guid isPermaLink="true">https://emweekly.samermetri.com/articles/aap-pediatric-uti-2026/</guid><pubDate>Mon, 26 Oct 2026 12:00:00 GMT</pubDate><description>The 2026 AAP guideline expands UTI guidance to medically noncomplex children from 8 days through 5 years and uses GRADE methodology. It suggests antibiotic courses of 7 days or less for most children, with age- and syndrome-specific durations, and recommends oral rather than hospitalization-requiring parenteral or sequential therapy for children older than 28 days and younger than 5 years who tolerate oral treatment and do not otherwise require admission. It also updates post-UTI imaging, including renal/bladder ultrasonography after a first febrile UTI and a suggestion against routine VCUG when ultrasonography is normal. AI-generated; Not yet human-reviewed.</description></item><item><title>VASSPR: earlier vasopressin did not reduce mortality</title><link>https://emweekly.samermetri.com/articles/vasspr/</link><guid isPermaLink="true">https://emweekly.samermetri.com/articles/vasspr/</guid><pubDate>Mon, 26 Oct 2026 12:00:00 GMT</pubDate><description>VASSPR was a pragmatic, open-label, cluster-randomized cluster-crossover strategy trial across 13 US hospitals involving 3,959 adults receiving vasopressors for septic shock. Hospitals alternated between recommending fixed-dose vasopressin 0.03 U/min when other vasopressors reached 0.1 versus 0.4 micrograms/kg/min norepinephrine-equivalent. Twenty-eight-day mortality was 31.8% versus 33.0% (adjusted marginal OR 0.98, 95% CI 0.87-1.06; adjusted risk difference -0.4 percentage points, 95% CI -2.7 to 1.3), with no difference in kidney replacement therapy-free days. AI-generated; Not yet human-reviewed.</description></item><item><title>CLOVERS: fluids first, or earlier vasopressors?</title><link>https://emweekly.samermetri.com/articles/clovers/</link><guid isPermaLink="true">https://emweekly.samermetri.com/articles/clovers/</guid><pubDate>Mon, 26 Oct 2026 12:00:00 GMT</pubDate><description>Historical sample. CLOVERS randomized 1,563 adults after initial fluid resuscitation to a restrictive strategy prioritizing vasopressors or a liberal fluid strategy. Death before discharge home by day 90 occurred in 14.0% versus 14.9% (difference -0.9 percentage points; 95% CI -4.4 to 2.6; P=0.61). AI-generated; Not yet human-reviewed.</description></item><item><title>DEVICE: first-pass success with video laryngoscopy</title><link>https://emweekly.samermetri.com/articles/device/</link><guid isPermaLink="true">https://emweekly.samermetri.com/articles/device/</guid><pubDate>Mon, 26 Oct 2026 12:00:00 GMT</pubDate><description>Historical sample. In 1,417 critically ill adults, video laryngoscopy achieved first-pass success in 85.1% versus 70.8% with direct laryngoscopy (difference 14.3 percentage points; 95% CI 9.9 to 18.7). Severe complications occurred in 21.4% versus 20.9% (difference 0.5 points; 95% CI -3.9 to 4.9). AI-generated; Not yet human-reviewed.</description></item></channel></rss>